Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in Pediatric Patients With Relapsing Remitting Multiple Sclerosis (LemKids)
NCT03368664Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Oct 2017
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of alemtuzumab in multiple sclerosis (MS), sponsored by Sanofi. Started Oct 2017; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03368664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03368664.